Creatv Bio, a division of Creatv MicroTech Inc, a liquid biopsy-based cancer diagnostic testing company, announced on Wednesday that it has opened its full service CLIA-certified laboratory in Monmouth Junction, New Jersey.
The new laboratory enables Creatv to provide its LifeTracDx Blood Test, which measures Cancer Associated Macrophage-Like cells (CAMLs) and Circulating Tumor Cells (CTCs), to companies developing and conducting oncology drug trials.
CAMLs have been shown to be detectable in the blood of most cancer patients in all subtypes of malignancies as well as predict treatment response to most therapies within 30-45 days following drug administration.
ImmunityBio secures US patent portfolio covering ANKTIVA combination therapy through to 2035
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
CelLBxHealth partners with AdventHealth on cancer monitoring studies
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
Atisama Therapeutics reports progress in Phase 1 study of RB042
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401
SN BioScience reports first patient dosed in global Phase 1b/2 clinical trial of SNB-101
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
AstraZeneca reports survival gains in Phase III bladder cancer trial
Creatv Bio opens CLIA-certified laboratory in Monmouth Junction, NJ
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing